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For the purpose of writing this paper, we have been to choose this subject as it 
is a core part of the pharmaceutical companies' business strategy for promoting 
medicines. Regarding the importance of the research theme and the business 
environment, it is crucial that anyone connected to this business should realize 
the importance of organization, details, good deployment and impact of each 
event. In this respect, marketing can be seen as a true system of economic 
activities related to the programming of products and services that have the role 
of satisfying the requirements of current and potential consumers considerably, 
but is also linked to prices, promotion and distribution products or services. 
Taking into consideration the importance that marketing has within the 
pharmaceutical field and the huge budgets that medical and pharmaceutical 
companies spend for the events organized in this domain, I consider that a 
company which is able to have a new approach and a new vision for the 
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organization of events and sharing medical education to doctors and medical 
information to patients will have a big success. 
 
Keywords: medicine; marketing; pharmaceutical industry; medicine promotion 
strategy. 
 




The pharmaceutical industry is a strategic component of the Romanian economy, 
having an essential contribution through the taxes paid to the state budget. In addition 
to this economic influence, the role of the pharmaceutical industry is growing in 
complexity through its major contribution of the health level of the population. 
People’s health definitely influences governmental strategies through the social 
implications that it brings to a long-term period. That is why it is extremely important 
to understand how this industry works, what are the forces that drive it and what are 
the variables that can be influenced to make operating mechanisms more efficient. 
This article aims to make a breakthrough in the Romanian pharmaceutical industry 
and to focus the reader’s attention on the important elements that define this industry 
and the areas of action that can be improved in general, and in particular, an analysis 
will be made on how a producer medicine promotes and sells medicines on the 
Romanian market. The Romanian pharmaceutical market is strongly influenced both 
by external factors and by internal factors. The analysis of these factors by marketing 
specialists leads to the development of appropriate strategies to meet the demands 
and competition in the market. A method commonly used in assessing external 
factors that influence the market is the Pestel Analysis which analysis the economic, 
political, social, cultural, institutional, technological and demographic variables. 
Romania has an internal and stable political climate that is reflected by stimulating 
factors in the pharmaceutical market. Multinational companies are encouraged to 
invest and come to Romania with state-of-the-art products. However, the economic 
inefficiency of governments over the last 20 years has led to the creation of a 
pressure by the Romanian state on the economic environment materialized by taxes 
to cover the lack of strategy and governmental efficiency. The pharmaceutical 
industry is fairly protected by changing economic conditions, because the demand for 
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medicines remains constant. Romania’s economic growth is reflected in the 
pharmaceutical industry through the presence of many multinational companies that 
have significantly diversified their product portfolios to better meet demand. 
Changes in social trends may have an impact on the demand for products. 
Consumers motivation and need identification in case of medicines are based on 
many personal, cultural and social factors such as: health perception, individual’s 
education and social norms, the general social framework related to public health, the 
norms of the group to which the individual belongs (family) [Gârdan & Geangu, 
2009]. The generic medicine has a great impact on the pharmaceutical industry due 
to its accessibility, causing fierce competition between generic companies, which is 
reflected in the final product price.  
At the same time, the patents’ expiring for original medicines and the emergence 
of much cheaper generics stimulate innovative companies’ actions to invest heavily 
in research and development to find new medicines. A society that develops from all 
points of view creates the premises for its members to hope for and to have a higher 
level of life that translates into a more effective medication, and in this case through a 
higher consumption of medicines.  
The pharmaceutical market in Romania is highly regulated and harmonized with 
the EU legislation. In Romania, the existence of strict legislation on fixed-term patent 
protection prevents many pharmaceutical companies from launching a new product 
on the market. The National Medicines Association (ANM) is the Romanian institution 
responsible for implementing and monitoring the application of legislation in the 
field of medicines. For a manufacturer to receive a Market Implementation 
Authorization (APP), it must comply with internationally agreed regulations. In order 
to receive APP, a generic medicine has to prove through bioequivalence studies by 
independent company that it is similar to concentrations and efficacy with the 
original medicine. The competition in the pharmaceutical industry is held in ethical 
limits by the Competition Council, which is a state body that is responsible for 
monitoring and correcting techniques of good practice in all industries. 
The system of values, customs, and traditions of the population encourages the 
pharmaceutical industry. The population of Romania perceives the medical profession 
as one of great importance and influence, treating with seriousness and respects the 
representatives of this profession. As a result, physicians have a great influence on 
the population and are a growth factor for the pharmaceutical industry. 
Progress and technological change put pressure on health systems. New 
generation medicines created with advanced technology that treats rare and serious 
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diseases have influenced and will influence in the future the dynamics of the 
Romanian pharmaceutical market. In Romania, there is an increasing trend of aging 
population. The number of births is less than the number of deaths. In the last 30 
years, Romania’s population has fallen naturally or due to migration by almost 20%. 
An aging population leads to an increase in the number of chronic diseases 
associated with age. This trend of aging and illness of the population directly affects 
and influences the pharmaceutical industry and the marketing strategies of companies 
in this field. 
 
General framework of pharmaceutical industry 
A conclusive picture of the pharmaceutical industry can also be seen in the 
analysis and influence of the 5 Forte Porter. [Epure, 2007] 
Threats of new entrants into this industry are low. In the pharmaceutical industry, 
there are high barriers to entry because of the high costs associated with research and 
development of new medicines. Patent protection can be an important barrier to 
generic medicine companies. 
Worldwide, the large amounts of money available in the pharmaceutical industry 
have led to a steady stream of new companies created. However, these smaller 
companies do not pose a serious threat to large pharmaceutical companies. In fact, 
one of the key exit strategies of a start-up investor in the pharmaceutical industry is 
selling to a large pharmaceutical company when new products are in the initial 
development phase. The only areas for which pharmaceutical companies are of 
particular interest (to develop new products) are niche such as hepatitis, immunological 
diseases, and cancer and biological medicines in the future. The global trend also 
applies to the pharmaceutical market in Romania and will remain continuing a steady 
trend for the coming years. Competitive rivalry in the pharmaceutical industry is 
extremely high. The high degree of competition is due to: strong market presence of 
multinational medicine companies and the opportunity arising from the expiry of the 
original medicines patent and the presence of a large number of generic medicines 
companies. The number of pharmaceutical companies is quite high in Romania (382 
records in Cegedim). However, the top 15 rankings account for 63% of the total 
market (the percentage is fairly stable in years). All companies fight for the same 
number of doctors, pharmacists and potential patients and, at the same time, for the 
same resources (insurance money). 
The trend for the next 5 years is that competition and rivalry will grow even 
more, mainly through: 
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− Making mergers and acquisitions; 
− Applying technology to increase efficiency. 
The negotiating power of buyers in the pharmaceutical industry varies according 
to their type. Of all stakeholders in the pharmaceutical industry, the customers have 
the slightest negotiating power because medicines are necessity products and in most 





− Health Insurance House (CAS). 
 
Pharmacists – Growing Negotiating Power 
Due to the legislation that allows selling without a prescription, the strength of the 
pharmacist is very high. Often, the purpose of the medical act is less influenced by 
the doctor and more influenced by the pharmacist who releases the brand with the 
best commercial advantage for him. Of all pharmacies, pharmacy national chains 
have the highest power, accounting for 30% of the total number of pharmacies, but 
more than 50% of total sales. Pharmacies are fighting for patients with their own 
marketing activities. The pharmaceutical chains, the more patients they have, the 
more bargaining power they have, and it will be more costly for manufacturers to sell 
their products in these pharmacies. The trend is that the strength of national 
drugstores will increase even further in the years to come. They buy individual 
chains or local pharmacies, conquering the market. The Romanian market is very 
attractive in this area, so one of the biggest players in the EU as pharmacies (Dr. 
Max) has already entered Romania and will develop next year by purchasing the 
second chain Pharmacies in Romania (SSB). As for individual pharmacies – their 
power is getting smaller and the prognosis is that they will disappear over the next 10 
years. In 10 years, there will be more or less four types of very strong pharmacies: 
national chains, local chains, virtual chains and purchasing groups. 
 
Doctors – MEDIUM Negotiating Power, Decreasing in Power 
Doctors can only prescribe the molecule on recipe. However, the strength of 
doctors in choosing the brand to be bought by the patient has dropped dramatically in 
recent years. There are strictly regulated differences in what each physician can 
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prescribe: general practitioners and specialists. There are protocols and different 
types of compensation lists. The future trend will be that the power of physicians will 
increase when they prescribe original products (which, as mentioned above, will 
primarily be niche or biologic medicines), but still moderate and low tendencies for 
generic prescription medicines. 
 
Patients – REDUCED Power of Negotiation 
Now, in Romania, most patients rely on prescriptions from doctors or pharmacists 
when it comes to RX medicines in particular (it is also true for OTC products, but not 
for RX). Knowing that in the next 10 years, Y-generation components will be the 
main buyers, we can predict that their concentrated attention and increased education 
will increase decision-making, taking into account not only the price (as in most 
cases now), but also the quality. So the trend is that patients’ influence will increase 
over the next 10 years. They will take more care of the options they have in 
treatments and the quality of products and services. 
 
Health Insurance House (CAS) – Huge negotiating power, and will maintain its 
dominant position 
 Limitation of prices for compensated medicines is very strict: generic companies 
may have a maximum of 65% of the original price and the lowest price in the EU 
countries where they are sold. The trend of the coming years will be: reduced funding 
and inefficient use of public resources, plus increasing the number of chronic 
diseases. For this reason, the government will continue to focus in the coming years 
on introducing cost-saving measures such as the lowest EU price and claw-backs. 
 
The Negotiating Power of Suppliers in the Pharmaceutical Industry is Medium 
Medicine distributors buy goods and pharmaceutical products from producers 
(foreign or domestic) and sell them to pharmacies in Romania. They have their own 
logistics and sales force. So besides taking orders and bringing medicines to 
pharmacies, they also have marketing activities. Based on these, they can influence 
the sales of products in pharmacies and have enough negotiating power. More than 
10 years ago, distributors had the logistics of the whole process, and it was the 
moment when they began to create and develop their sales forces and have their own 
commercial approach (linked to producers). More recently, distributors began to 
develop in two different directions: 
− Promotion teams focusing on a producer / brands; 
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− Extending their activities by creating virtual pharmacy chains (VPCs) consisting 
of grouping more individual pharmacies under the same concept and design in strict 
correlation with the commercial approach (VPCs acquire medicines exclusively or 
mainly from the VPC vendor). 
Due to the decrease in prices and the claw-back taxes, the commercial conditions 
offered by the producer to the distributor decreased dramatically. Cumulative 
conditions, bargaining power and retailers’ profitability tend to fall. Having 
anticipated this in advance, they have developed and created new areas that will help 
them maintain the same level of negotiation and profitability. In order to better 
control the distribution chain, many distributors merged with national or international 
medicine chains or created their own chain of pharmacies (for example, Fildas 
Distributor – Catena Pharmacy). The trend for the coming years will be that 
distributors will maintain their power by focusing on: 
− own promotional teams (high skills, team hire); 
− new technologies developed to reach pharmacies will provide strong penetration 
in pharmacies; 
− increasing the VPC’s activities and power; 
− fusion between pharmacies’ distributors and chains or the creation of distributor 
pharmacies. 
 
The Threat of Substitutes in the Pharmaceutical Industry  
The threat of substitutes in the pharmaceutical industry is medium. As substitutes 
for medicines, we can talk about new trends in the use of “natural solutions” for 
treating diseases. Helped by increased Internet access and information, over the past 
10 years, the substitute medicine with “natural ingredients” has been greatly 
promoted, with more and more followers. The information “sold” by replacement 
products (generally, dietary supplements) is not regulated by any law (all medicines, 
including OTC medicines, are strictly regulated in terms of communication with the 
professional public or the general public). Due to this situation, misleading problems 
can occur and the increase in excess consumption of supplements is favoured. The 
trend is that if the legislation does not change, the consumption of supplements will 
increase at the expense of medicines and the major diseases risk being untreated. A 
similar situation is also found in vaccines cases where an important part of the 
population refuses to vaccinate because of media poisoning. Another trend or “hope” 
is that, if the education of the new generations is higher, it will increase the 
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addressability for the healthcare professionals, and the tendency to substitute 
medicines will decrease. 
Segmentation, Targeting and Positioning of Products on the Market  
Segmentation, targeting and positioning of products on the market are other tools 
used by marketing specialists to achieve competitive advantage in pharmaceutical 
industry. The Romanian pharmaceutical market, by its size and complexity, puts real 
problems on marketing specialists in defining appropriate sales and marketing 
strategies. By segmenting the pharmaceutical market, it is desired to divide it into 
definable, accessible, profitable growth parts or potential growth segments, which 
can be monitored for a good implementation of marketing strategies. Through this 
method, marketing specialists can identify market segments that are compatible with 
their promotion and sales strategies. At the same time, marketing teams can monitor 
the implementation and the consequences of their strategies within a defined period 
of time. 
 
The Financial Resources of the Marketing Teams in the Pharmaceutical Industry  
The financial resources of the marketing teams in the pharmaceutical industry are 
limited. That is why there is an acute need to segment the market and channel 
resources into areas of potential and interest for pharmaceutical manufacturers and 
distributors. Segmentation of the representative market for the pharmaceutical 
industry is achieved by disaggregating the market in geographic segments. The 
Romanian pharmaceutical market is segmented in the first phase at the level of the 
counties and at the level of the micro segmentation it reaches the level of the city or 
parts of the city, in case we speak of big cities. Since all pharmaceutical companies 
report and receive market information from the same authorized data providers, then 
their marketing strategies can be better adapted to market conditions and competition. 
The most well-known segmented data providers in Romania are Cegedim and IMS. 
 
Variables for Market Segmentation 
In the pharmaceutical industry, segmentation of the market takes into account 
several variables. Firstly, account is taken of geographical and demographic variables 
on the market. Another important variable that is taken into account in industry is 
related to the operational characteristics of the pharmaceutical industry. Not all 
companies in the pharmaceutical industry have proper budgets to cover selling and 
promoting the entire Romanian pharmaceutical market. This is why there is a need 
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for geographically differentiated segmentation to create targeted marketing strategies 
on areas of interest or areas where companies have sales and promotion teams. 
Another variable that may influence market segmentation is situational and may be 
internal or external to the pharmaceutical industry, and may be related to the 
seasonality of certain pharmaceutical products or to the economic cycle. Other 
variables that may occur in segmentation may be related to the personal 
characteristics of customers or the special relationships that exist between clients and 
pharmaceutical industry players. For players from the pharmaceutical industry, 
targeting the market is a natural approach to trying to get commercial profit. 
Targeting the market must be done taking account of some logical steps starting from 
the general and reaching individual. As a first step in pricing the market, we must 
make a prediction on the size and direction of the market in the coming period. Then, 
the profiles of the segments where we will act should be identified and determined, 
followed by a prediction of their future dimensions. Once these predictions are done, 
in the next step the marketing strategy for each segment is defined and the potential 
for profit is predicted. 
 
The Positioning of Products in the Pharmaceutical Industry 
The positioning of products in the pharmaceutical industry is extremely restrictive 
and strictly regulated by the National Medicines Agency (ANM). This positioning of 
the medicines should be approved by the ANM and must follow the unique 
Marketing Placement Authorization (APP) guidelines. As a free translation, this 
means that the placement of a medicine on the market is strictly based on pathologies 
approved in the package leaflet. It is forbidden to promote off-label medicines on 
pathologies other than those approved. It is possible that some medicines in 
Romania have been approved for sale and release of less pathology than in other 
European countries. These approvals are exclusively granted by the ANM. Taking 
into account these positional restrictions, pharmaceutical companies are forced to 
innovate in marketing strategies to position their products appropriately and to 
achieve their value-added currencies in Romania. The perceptions of patients is 
mainly influenced by the explicit communication made by doctors and medical 
personnel, also other patients consumption experiences [Geangu et al., 2010]. The 
positioning of the products of the manufacturing companies on the Romanian 
market takes into account several variables. One of the positioning approaches 
takes into account the major attributes of the products compared to the competition. 
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On the same therapeutic area and on the same medicine molecule, manufacturers 
position their products on the basis of some additional qualities and added value to 
their competitors. Other medicine placement takes into account the life cycle of a 
medicine. Many of the medicines on the Romanian market are outdated both as 
efficacy compared to other medicines as well as the incidence of adverse reactions 
or as compliance and adherence of patients to treatment. Many medicines on the 
market are from the old generation and are at the end of their life cycle. The goal of 
the manufacturers is to position their medicines in positions capable to replace 
those older medicines with lower efficacy or with a greater number of daily 
administrations with new medicines. Studies have shown that patients generally 
forget or refuse to take certain doses of medication in the day as the number of 
administrations is higher or the taste of administrated medicine is worse to assimilate. 
Manufacturers are trying to increase the compliance and adherence of patient in 
Romania by bringing and positioning new generation medicines in a single daily 
administration or easy administration to replace older generic medicines. 
By continuous positioning, medicine manufacturers adapt their marketing 
strategies and, depending on the stage of life cycle, products for sale and promotion. 
Some pharmaceutical manufacturers also position their medications according to 
the perceptions of clients (doctors and pharmacists) and patients about quality and 
safety. Much of the pharmaceutical companies are purchasing raw materials from 
countries like China or India where standards of efficiency, quality and safety do 
not match European standards. Thus, some European manufacturers place their 
medicines at the level of doctors, pharmacists and patients’ perception as effective 
and safe and made to high European standards as opposed to competition. 
 
All Marketing Strategies Are Centred on Marketing Mix 
Marketing specialists in the pharmaceutical industry are constantly searching for 
the perfect marketing mix to maximize their profits. All marketing strategies are 
centred on the 4 P: product, price, positioning, and promotion. The mix of these 
variables makes the difference between medicine companies. When talking about the 
product in the pharmaceutical industry, and in the case of medicine manufacturers, 
we are talking about both a tangible good that identifies itself with the medicine and 
an intangible good that refers to a service. The intangible service that medicine 
manufacturers make with the help of medical representatives is the medical 
education provided to healthcare professionals. Taking into account the dynamics of 
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the medical industry, it is impossible for a physician to keep up with the new medical 
information related to pathologies and appropriate medication. International medical 
treatment guidelines are improving rapidly according to the new medical studies 
published. On the Romanian market are approved and marketed tens of thousands of 
medicines that are hard to remember and assimilated by medical specialists without 
the help of the medicine manufacturers. That is why we can say that medicine 
manufacturers are in addition to medicine suppliers and service providers with useful 
medical information for physicians and pharmacists for the benefit of patients. 
The products that marketers promote on the Romanian market can be classified 
into two main categories: RX (medicines with medical prescription) and OTC 
(medicines without prescription). RX products may only be recommended by 
physicians due to the risks and consequences that may arise from the ingestion of 
these medicines. OTC (Over the Counter) products can be consumed and purchased 
without a prescription because of the low risks involved in overconsumption or 
inappropriate consumption. 
The price of RX medicines is regulated on the Romanian market by the National 
Medicines Agency and published officially in the annual catalogue of CANAMED 
medicines. The ANM requires all APP holders’ maximum medicine prices and at the 
same time obliges medicine manufacturers to register their medicines in Romania at 
the lowest price of 12 European standard countries. As producers of medicines, they 
have to take into account another additional variable, namely the pricing of medicines 
and the price of competition. Medicine prices have suffered and are permanently 
subject to changes and adjustments based on company strategies or price movements. 
In the case of compensated medicines, the Romanian state offers a subsidy to each 
insured by reducing the co-payment it has to pay for the purchase of pharma 
medicines. This copayment represents a specific percentage determined by the ANM 
on various pathologies (50%, 100%) and relates to the lowest-priced medicine in that 
class. 
The only way to play with prices and increase profitability is with the OTC 
medicine pricing strategy. These medicines, which are released without medical 
prescription, do not have price-setting constraints, as is the case with Rx medicines. 
That is why it is extremely important for a medicine manufacturer to have a complete 
and comprehensive OTC medicine portfolio that will increase the company’s profit 
margin. In the case of generic OTC medicines, manufacturers try not to enter into a 
price war that may erode profit margins. There is also the risk that by eroding prices, 
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customers will no longer have confidence in the qualities of the medicine offered at a 
too low price. In the mind of the Romanian consumer a cheap medicine is associated 
in thinking in most cases with a bad medicine. There are few cases where patients 
require expensive medication from doctors, assuming that if expensive it is also very 
good.  
 
Advertising in the Pharmaceutical Industry 
Advertising in the pharmaceutical industry is strictly regulated by the National 
Medicines Agency. It is forbidden to use mass advertisements for prescription 
medicines (RX). Advertising is only allowed for medical specialists, physicians or 
pharmacists, and only in specific contexts, such as specialized pharmacies or in 
symposiums and congresses where access to the public is limited. Instead, in the case 
of OTC medicines with a non-prescription, advertising is allowed on any media 
channel. Medical promotion is a marketing tool widely used in the pharmaceutical 
industry. The multitude of medicines present on the Romanian market makes it 
virtually impossible for the medicine manufacturers to be seen by the medical 
industry specialists and to persuade them to prescribe or recommend without the help 
of medical team representatives to promote the medicines. 
 
Medical Promotion – Basically a Sales Process 
Medical promotion is basically a sales process. Medicines at pharmacies cannot 
be sold without a prescription from a doctor. The doctor would not know of a 
medicine on the market if he did not been promoted. The promotional team brings 
medical information to healthcare professionals in pharmacies and medical 
institutions, discovering their needs for patients on their clients, and selling those 
strict benefits that cover their needs. So promotion is a sale of benefits that cover the 
needs in order to get the recommendation. The placement of medicines in the 
Romanian pharmaceutical market is done through distributors. They buy large 
quantities of medicines from manufacturers, store them and distribute them in 
smaller quantities to pharmacies where they have business relationships. At the 
national level, the most important distributors are: Farmexpert, Farmexim, Mediplus, 
Fildas, Dona Logistics, Pharmafarm. Most pharmaceutical manufacturers sell their 
medicines in Romania via two-level distribution channels. One is the level of 
national distributors and the second is that of pharmacies that make the final sale to 
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patient clients. The type of distribution chosen by the majority of producers for the 
Romanian market is the selective distribution which grants the right to distribute 
medicines to a limited number of collaborators. 
Conclusions 
In order to be successful in the Romanian pharmaceutical market, it is necessary 
to develop and implement complex marketing strategies that will ensure competitive 
advantage in an over-crowded field of competitors. 
In order to continue with a sustained growth of this market, a well-informed 
consumer is needed and, in this respect, the service offered by the pharmacy offices 
is becoming a key and differentiating aspect compared to other channels. Medicine 
producers and doctors play a key role in the development of a sustainable system: 
health and wellness culture as the main added value that will be enhanced in the 
coming years. Current consumption trends will help us identify the future of the 
pharmaceutical market. 
The prescription of generic medicines should be encouraged, as other countries 
have been doing, both to achieve a more appropriate use of the medicine and to 
stimulate competition in the market by eliminating the strong economic barrier 
represented by the commercial brand in medicines. 
The prices’ vector of a market and the quantities consumed is the result of the 
interaction between producers, funders, prescribers and consumers of medicines, all 
of them reacting with imperfect information to the actions of the others. While such a 
scenario of actions and reactions has a dynamic nature, the regulatory framework 
designed must take into account not only the clinical and pharmacological aspects of 
the medicine sector, but also the interaction mechanisms that occur within the supply 
and demand of these products. Thus, market structures are the result of the offer’s 
ability to establish prices and criteria to differentiate its products, presenting cases of 
greater competition or greater concentration, affecting the intervention policy of the 
regulator. From another perspective, greater diversity in supply atomizes the ability 
of producers to establish rules of the game, facilitating the operation of cost-effective 
prescription patterns. Also, differentiated market structures within the pharmaceutical 
sector require specific intervention mechanisms, there being an extended palette of 
policies.  
Product-based strategies will be focused on adding features that determine an 
additional benefit for the customer. These characteristics in the case of a the 
pharmaceutical product will focus on the packaging, the pharmaceutical form and the 
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substance that compose it. For the packaging, one could include new attributes such 
as color, biodegradable materials and so on. For the pharmaceutical form, we could 
replace the tablet with the soft capsule, to reduce the risk of falsification, but also to 
improve its speed of action and bioavailability. For the substance, one could include 
excipients that are less harmful to health. It can be concluded that all the 
characteristics added to the Product must fundamentally be aimed at giving greater 
added values represented in benefits for the final consumer. An example of added 
value is free home delivery for the purchase of pharmaceutical products in some 
pharmacies. 
On the other hand, promotion-based strategies have very well defined 
characteristics such as the following: 
• Personal Sale: It is the direct and personal or telephone presentation of a product 
to the final consumer through a representative of the pharmaceutical organization. 
• Advertising: It is a form of not personal communication that is usually done 
through mass media such as internet, newspapers, radio and television. 
• Sales Promotion: It is a demand stimulating activity to complement personal 
sales and advertising information such as: 2x1offers, organization of draws for 
amounts in purchases, acquire the second pharmaceutical product at half price and so 
on 
• Public Relations: Public relations, as a form of communication to a target 
audience in order to obtain favorable attitudes and opinions about our product, can 
take many forms, such as sponsorship of medical events, lobbying and so on. 
The distribution strategies are based on the following aspects: Offer certain 
pharmaceutical products exclusively, use intermediaries, offer pharmaceutical 
products through the internet or by telephone, delivering the pharmaceutical products 
at home and so on. 
 
Directions for Future Research  
Regarding the content of the present work, one would identify certain directions 
for future research: 
− quantitative research based on field survey regarding consumers’ perception of 
medicines regarding the degree of trust in producers and/or the chains of established 
pharmacies; 
− research on the degree of efficiency of media channels used for the promotion of 
medicines; 
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− qualitative research of focus group type regarding the decision-making process 
of buying medicines for young consumers; 
− research on general population perception of possible consumption problems; 
− research on perception of young people on possible consumption problems and 
associated risk situations; 
− research on accessibility to the health system of all social groups; 
− research regarding the impact of prevention policies on the use of some 
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